Clindataceutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-01-2025
- Paid Up Capital ₹ 0.10 M
as on 08-01-2025
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -0.12%
(FY 2022)
- Profit -215.84%
(FY 2022)
- Ebitda -234.89%
(FY 2022)
- Net Worth -215.81%
(FY 2022)
- Total Assets 198.45%
(FY 2022)
About Clindataceutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Naresh Namani and Suresh Azmeera serve as directors at the Company.
- CIN/LLPIN
U33100TG2018PTC122446
- Company No.
122446
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Feb 2018
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Clindataceutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Namani  | Director | 22-Feb-2018 | Current |
| Suresh Azmeera | Director | 24-Mar-2022 | Current |
Financial Performance of Clindataceutics.
Clindataceutics Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 0.12% decrease. The company also saw a substantial fall in profitability, with a 215.84% decrease in profit. The company's net worth observed a substantial decline by a decrease of 215.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clindataceutics?
In 2019, Clindataceutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clindataceutics?
Clindataceutics has a workforce of 6 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clindataceutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clindataceutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
